The NUVISAN Group is a successful, globally active and independent Clinical Research Organization (CRO), which conducts clinical research Phases I through III with a special focus on Oncology. Well over 2,500 pharmaceutical studies have been conducted since the company was founded. Along with complementary divisions focusing on bioanalytics, biopharmaceuticals, pharmaceutical analysis, stability testing and clinical trial supply production and packaging, the Nuvisan Group is able to offer comprehensive services in all areas of clinical pharmaceutical development from a single source. Founded in 1979 and headquartered in Neu-Ulm, Germany, the approx. 450 highly qualified employees of the NUVISAN Group around the world provide the pharmaceutical industry with the experience and expertise needed in todays competitive environment. In addition to NUVISAN GmbH, other companies belonging to the NUVISAN Group include FOCUS Clinical Drug Development GmbH and Essex Pharma Development GmbH. NUVISAN has been a member of the ADCURAM Group AG since May 11, 2010.